Background & Aims The risk of hepatocellular carcinoma (HCC) during antiviral therapy in
patients with chronic hepatitis B (CHB) is inadequately predicted by the scores built from
untreated patients. We aimed at developing and validating a risk score to predict HCC in
patients with CHB on entecavir or tenofovir treatment. Methods This study analysed
population-wide data from the healthcare databases in Taiwan and Hong Kong to identify
patients with CHB continuously receiving entecavir or tenofovir. The development cohort …